Wellington Management Group LLP Lowers Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Wellington Management Group LLP decreased its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 78.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,411 shares of the specialty pharmaceutical company's stock after selling 34,218 shares during the quarter. Wellington Management Group LLP's holdings in ANI Pharmaceuticals were worth $561,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the company. Innealta Capital LLC bought a new position in ANI Pharmaceuticals in the second quarter valued at approximately $65,000. Ridgewood Investments LLC acquired a new stake in ANI Pharmaceuticals in the second quarter valued at about $85,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in ANI Pharmaceuticals by 24.2% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company's stock worth $177,000 after purchasing an additional 579 shares in the last quarter. XTX Topco Ltd bought a new position in shares of ANI Pharmaceuticals in the 2nd quarter valued at $207,000. Finally, HighTower Advisors LLC bought a new stake in shares of ANI Pharmaceuticals during the third quarter worth about $222,000. Institutional investors own 76.05% of the company's stock.

ANI Pharmaceuticals Stock Performance

ANIP traded down $0.91 during trading on Friday, hitting $53.35. 1,066,257 shares of the company traded hands, compared to its average volume of 225,876. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The firm has a market cap of $1.12 billion, a P/E ratio of -97.00 and a beta of 0.73. ANI Pharmaceuticals, Inc. has a one year low of $52.00 and a one year high of $70.81. The stock's fifty day moving average is $57.93 and its 200 day moving average is $60.09.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.09 by $0.25. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The firm had revenue of $148.30 million for the quarter, compared to analyst estimates of $144.37 million. During the same period in the previous year, the company posted $1.05 earnings per share. The business's revenue was up 12.5% on a year-over-year basis. As a group, equities analysts predict that ANI Pharmaceuticals, Inc. will post 3.87 EPS for the current fiscal year.

Insider Activity at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, CFO Stephen P. Carey sold 7,500 shares of the company's stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total value of $418,425.00. Following the transaction, the chief financial officer now directly owns 154,468 shares in the company, valued at $8,617,769.72. This represents a 4.63 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Nikhil Lalwani sold 33,481 shares of the business's stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $57.99, for a total value of $1,941,563.19. Following the transaction, the chief executive officer now directly owns 370,378 shares of the company's stock, valued at $21,478,220.22. The trade was a 8.29 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 42,231 shares of company stock worth $2,434,286. 12.70% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on ANIP. Leerink Partners assumed coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, December 11th. They issued an "outperform" rating and a $80.00 price target for the company. HC Wainwright reaffirmed a "buy" rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a report on Monday, November 11th. Truist Financial lifted their price objective on ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a "hold" rating in a research note on Tuesday, October 22nd. StockNews.com lowered shares of ANI Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Saturday, September 7th. Finally, Piper Sandler started coverage on ANI Pharmaceuticals in a report on Friday, October 11th. They set an "overweight" rating and a $68.00 price target for the company. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $77.71.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.